SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported preliminary takeover discussions involving Silver Lake and Saudi Arabias PIF are driving attention, with traders debating whether a potential offer would undervalue Unity and whether a deal will happen. The debate is reinforced by strong Q3 results, first-ever GAAP profitability and rapid Vector advertising growth, which some investors cite as reasons Unity may be worth more independently.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

A sharp, high-volume move has revived speculation about a Viking Therapeutics partnership or buyoutoften naming Novo Nordiskbut no deal is confirmed. Traders are split between expecting a catalyst or short-covering squeeze and calling the rally another rumor-driven pump; upcoming VK2735 trial milestones and obesity-drug prospects underpin the bullish case.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger quarter and raised outlook, supported by demand for its Wegovy pill, have renewed recovery optimism. Traders see oral obesity treatments and international expansion as growth drivers, while others remain cautious about Lillys competition, diabetes weakness and pricing pressure.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA decision on ivonescimab for EGFR-mutated lung cancer is the dominant catalyst, with traders debating approval versus a possible rejection or delay. The debate centers on the drugs strong progression-free-survival results and favorable survival trend versus the FDAs stated need for statistically significant overall-survival evidence, driving uncertainty around the binary outcome.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL leukemia-trial readout is the dominant catalyst, with traders focused on whether GPS meets its survival endpoint. Bullish anticipation of a major revaluation and short squeeze is countered by concerns that the binary results could disappoint; sharp price swings have also fueled claims of short pressure and manipulation, which remain speculation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt resignation and uncertainty over Nvidias next CEO dominate discussion, with traders debating whether he could return or whether an outside successor will be named. Speculation about China-related chip diversion and export-control scrutiny adds to concerns about governance and future guidance, while bulls argue the companys AI business remains strong.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra shares are under pressure after the European regulator reaffirmed its negative opinion on arimoclomol (Miplyffa) for Niemann-Pick disease type C, with the European Commissions final decision still pending. Traders are divided on the selloff: some see the setback as largely expected and an overreaction given the existing U.S. business, while others fault management and view the lost European opportunity as significant.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Persistent inflation and expectations of further Fed rate hikes are keeping Treasury yields elevated and weighing on TLT. Traders are split: some see a softer monthly PPI reading and recession risk as potential support for bonds, while others expect yields to keep rising.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmaxs better-than-expected Q3 results, with strong revenue growth and a return to profitability, are driving attention. Traders are reacting bullishly and discussing further momentum or a squeeze, while some caution that a one-time payment boosted reported revenue and question the quality of recurring earnings.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Virs discounted public share offering is driving the sharp selloff, with traders focused on dilution and questioning the need to raise more capital despite the companys substantial cash balance and positive hepatitis D Phase 3 results. Some investors argue the raise strengthens the balance sheet ahead of upcoming trials, while others see the discount as damaging to shareholder value and management credibility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NVDA Earnings tuesday, after hours. Options imply a 10% move for next week so 170 or 145 is a good guideline. Either way, not much price discovery after this week. A lot of uncertainty is currently priced into the stock. Overdone? Quite likely but the market will likely take a while to digest the situation. Headline risk remains. Terrible performance over the last month, down over 30%. I am not initiating any new purchases nor am I selling until earnings now. Expecting a beat. $AMD $SPY

Raghunath c balan

OnlyBuysDips

Ryan Young

steve clarke

StockTwits Web

Advanced Micro Devices Inc

 Earnings tuesday, after hours. Options imply a 10% move for next week so 170 or 145 is a good guideline. Either way, not much price discovery after this week. A lot of uncertainty is currently priced into the stock. Overdone? Quite likely but the market will likely take a while to digest the situation. Headline risk remains. Terrible performance over the last month, down over 30%. I am not initiating any new purchases nor am I selling until earnings now. Expecting a beat. 

RecklessTortuga

@RecklessTortuga 

From a base price down 30%, you think the news will drive it down another 10%?  Wow, you’re a thinking man!

StockTwits for iOS

 

From a base price down 30%, you think the news will drive it down another 10%?  Wow, you’re a thinking man!

Ihatenonsense

@Ihatenonsense markets can remain irrational longer than you can remain solvent.

 markets can remain irrational longer than you can remain solvent.

@RecklessTortuga it was looking very bright pre market high lol. I guess we&#39;ll find out.. should i sell cover call and buy puts for insurance?

StockTwits For Android 

 it was looking very bright pre market high lol. I guess we'll find out.. should i sell cover call and buy puts for insurance?

@TheBullKiller11 buying puts as insurance is never a bad thing. But I only sell covered calls when I believe a stock is overbought or expensive and NVDA doesn’t fit either category here. Personally, I’m not interested in adjusting my position with any further derivative or equity purchases/sales till after earnings. The low could be in. It also might not be. The company is in crisis. Headline risk exists

 buying puts as insurance is never a bad thing. But I only sell covered calls when I believe a stock is overbought or expensive and NVDA doesn’t fit either category here. Personally, I’m not interested in adjusting my position with any further derivative or equity purchases/sales till after earnings. The low could be in. It also might not be. The company is in crisis. Headline risk exists